Addex Completes Turnaround, Prepares For Phase III Dyskinesia Study
Executive Summary
Geneva, Switzerland-based Addex Therapeutics has raised CHF40m to pursue its novel negative allosteric modulator in a late-stage study for levodopa-induced dyskinesia associated with Parkinson's disease.
You may also be interested in...
Provention Announces First Clinical Trial Delay, Others Follow As COVID-19 Concerns Persist
Rather than expose patients and others to SARS-CoV-2, Provention opted to pause a Phase III type 1 diabetes trial. Addex and Iveric have since delayed trial initiations and more studies are likely to be impacted as coronavirus concerns mount.
Indivior Pact Buys Addex Time For Progressing Dipraglurant And Pipeline
Addex Therapeutics says its licensing deal with Indivior to develop and commercialize its investigative addiction therapy ADX71441 'buys time' to find resources for progressing its own pipeline.
Acadia Expects Broad Nuplazid Reimbursement; Pricing Soon
Acadia Pharmaceuticals Inc. has not yet priced its newly approved Parkinson's disease psychosis (PDP) drug Nuplazid (pimavanserin), but anticipates it will be covered by a vast majority of payers. The PDP approval also sets the stage for expanding Nuplazid's use into other indications, including Alzheimer's disease psychosis and agitation.